Trial · NCT01773187

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187, Phase 3, Terminated, CTI BioPharma; results first posted 2020-09-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pacritinib Versus Best Available Therapy to Treat Myelofibrosis. Trials, record NCT01773187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01773187

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT number: NCT01773187
Status: Terminated
Phases: Phase 3
Enrollment: 327 participants, actual
Lead sponsor: CTI BioPharma
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy
First posted: 2013-01-23
Last updated: 2020-09-29
Results first posted: 2020-09-29

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Spleen Volume Reduction	Baseline to Week 24	Number of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)
Secondary	Total Symptom Score (TSS) Reduction	Baseline to Week 24	Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Spleen Volume Reduction	Baseline to Week 24		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Total Symptom Score (TSS) Reduction	Baseline to Week 24	The original version (MPN-SAF TSS) was administered to the first 179 subjects enrolled in the study. The subsequent 148 enrolled subjects were administered the MPN-SAF TSS 2.0 and comprise the ITT population for this endpoint.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Spleen Volume Reduction	Pacritinib	42	Participants
Spleen Volume Reduction	Best Available Therapy	5	Participants
Total Symptom Score (TSS) Reduction	Pacritinib	19	Participants
Total Symptom Score (TSS) Reduction	Best Available Therapy	5	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pacritinib	220
Overall Study	STARTED	Best Available Therapy	107
Overall Study	COMPLETED	Pacritinib	167
Overall Study	COMPLETED	Best Available Therapy	75
Overall Study	NOT COMPLETED	Pacritinib	53
Overall Study	NOT COMPLETED	Best Available Therapy	32

Source ClinicalTrials.gov

Adverse events108

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypertension	Vascular disorders	Pacritinib	11	220	11
other	Hypertension	Vascular disorders	Best Available Therapy	0	106	0
other	Fatigue	General disorders	Pacritinib	33	220	33
other	Fatigue	General disorders	Best Available Therapy	9	106	9
other	Oedema peripheral	General disorders	Pacritinib	24	220	24
other	Oedema peripheral	General disorders	Best Available Therapy	16	106	16
other	Pyrexia	General disorders	Pacritinib	17	220	17
other	Pyrexia	General disorders	Best Available Therapy	11	106	11
other	Asthernia	General disorders	Pacritinib	16	220	16
other	Asthernia	General disorders	Best Available Therapy	7	106	7

1 to 10 of 108Source ClinicalTrials.gov

See all 108 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pacritinib	27	220
Total, all-cause mortality	Best Available Therapy	3	106
Total, other adverse events	Pacritinib	207	220
Total, other adverse events	Best Available Therapy	81	106
Total, serious adverse events	Pacritinib	117	220
Total, serious adverse events	Best Available Therapy	33	106

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
28336242	BACKGROUND	PubMed
33275766	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Pacritinib vs Best Available Therapy: Spleen Volume Reduction	Trial comparisons
Pacritinib vs Best Available Therapy: deaths from any cause	Trial comparisons
Pacritinib vs Best Available Therapy: Total Symptom Score (TSS) Reduction	Trial comparisons
Pacritinib vs Best Available Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01773187

GET https://conductscience.org/api/trials/v1/NCT01773187/events?page=2

API reference For AI assistants